6ps0: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==XFEL beta2 AR structure by ligand exchange from Alprenolol to Carazolol.== | |||
<StructureSection load='6ps0' size='340' side='right'caption='[[6ps0]], [[Resolution|resolution]] 3.40Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6ps0]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PS0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PS0 FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CAU:(2S)-1-(9H-CARBAZOL-4-YLOXY)-3-(ISOPROPYLAMINO)PROPAN-2-OL'>CAU</scene>, <scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
[[Category: | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ps0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ps0 OCA], [http://pdbe.org/6ps0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ps0 RCSB], [http://www.ebi.ac.uk/pdbsum/6ps0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ps0 ProSAT]</span></td></tr> | ||
</table> | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN]] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Batyuk, A]] | |||
[[Category: Cherezov, C]] | |||
[[Category: Gati, C]] | |||
[[Category: Han, G W]] | |||
[[Category: Ishchenko, A]] | |||
[[Category: Iwata, S]] | |||
[[Category: Joti, Y]] | |||
[[Category: Li, C]] | |||
[[Category: Liu, W]] | |||
[[Category: Moraes, I]] | |||
[[Category: Nakane, T]] | |||
[[Category: Nango, E]] | |||
[[Category: Shiriaeva, A]] | |||
[[Category: Stauch, B]] | |||
[[Category: Tanaka, R]] | |||
[[Category: Tono, K]] | |||
[[Category: Weierstall, U]] | |||
[[Category: Zatsepin, N A]] | |||
[[Category: Alprenolol]] | |||
[[Category: B2ar]] | |||
[[Category: Beta2ar]] | |||
[[Category: Carazolol]] | |||
[[Category: Complex-lcp method]] | |||
[[Category: Drug design]] | |||
[[Category: Gpcr]] | |||
[[Category: Lcp-sfx]] | |||
[[Category: Ligand exchange]] | |||
[[Category: Membrane protein]] | |||
[[Category: Sbdd]] | |||
[[Category: Xfel]] | |||
Revision as of 11:07, 13 November 2019
XFEL beta2 AR structure by ligand exchange from Alprenolol to Carazolol.
| ||||||||||||
